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Consumer interest in healthy lifestyle and health-promoting natural products is
a major driving force for the increasing global demand of biofunctional dairy
foods. A number of commercial sources sell synthetic formulations of bioactive
substances for use as dietary supplements. However, the bioactive-enrichment of
health-oriented foods by naturally occurring microorganisms during dairy fermentation
is in increased demand. While participating in milk fermentation, lactic acid
bacteria can be exploited in situ as microbial sources for naturally enriching
dairy products with a broad range of bioactive components that may cover
different health aspects. Several of these bioactive metabolites are industrially and
economically important, as they are claimed to exert diverse health-promoting activities
on the consumer, such as anti-hypertensive, anti-inflammatory, and anti-diabetic,
anti-oxidative, immune-modulatory, anti-cholesterolemic, or microbiome modulation.
This review aims at discussing the potential of these health-supporting bacteria as
starter or adjunct cultures for the elaboration of dairy foods with a broad spectrum of
new functional properties and added value.
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BIOFUNCTIONAL FOODS
Today foods are not intended to only satisfy hunger and to provide necessary nutrients for humans,
but also to prevent nutrition-related diseases and improve consumers’ health (Siro et al., 2008;
Gortzi et al., 2015). Increasing consumer demand and interest in obtaining additional benefits from
food has stimulated functional foods to emerge on the market, with USA, Europe, and Japan being
the dominant markets.
Although there is no unitary accepted definition, functional foods can be described as an
ordinary food that has components or ingredients added to provide a specific health benefit,
other than a purely nutritional effect. Ideally, functional food refers to an existing traditional
food product that is intended to be consumed as part of a normal diet and has a demonstrated
added physiological benefit (Siro et al., 2008). Therefore, it could not be in the form of pill
or capsule. The concept of biofunctional foods is generally used when this desirable biological,
medical, or physiological effect is exerted by microorganisms (Gobbetti et al., 2010). The health
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FIGURE 1 | Beneficial effects resulting from the consumption of biofunctional fermented dairy foods. Lactic acid bacteria participating in milk fermentation
in situ release and naturally enrich the fermented dairy product with a broad range of bioactive metabolites. Subsequent ingestion of this product can exert important
health-promoting activities on the consumer, such as anti-hypertensive, and anti-diabetic, immune-modulatory, anti-cholesterolemic or microbiome modulation.
benefits of these microorganisms can be exerted either directly
through the interactions of ingested live microorganisms with the
host (probiotic effect), or indirectly by ingestion of the microbial
metabolites synthesized during fermentation (bioactive effect)
(Stanton et al., 2005; Gobbetti et al., 2010; Joshi, 2015).
Probiotic Foods
Lactic acid bacteria (LAB) have been used to ferment foods for
at least 4000 years (Rotar et al., 2007). Although the probiotic
concept has expanded more recently, we have been unconsciously
ingesting beneficial microbes with traditional fermented foods
since ancient times. Fermented foods are the main carriers to
deliver probiotics (Figure 1). Among them, dairy products (in
particular fermented milks and yogurt) are by far the most
efficient and widely used (Giraffa, 2012). Cheese is a dairy product
which has a good potential for the incorporation of probiotic
cultures due to its specific chemical and physical characteristics
compared to fermented milks (higher pH value and lower titrable
acidity, higher buffering capacity, greater fat content, higher
nutrient availability, lower oxygen content, and denser texture).
These conditions facilitate survivability of probiotic strains and
tolerance to the low pH conditions encountered during gastric
transit (Karimi et al., 2011). Utilization of probiotics has been
optimized in several cheese varieties such as Cheddar, Gouda,
Camembert, Cottage type, white-brined, and traditional cheeses,
among others (Araujo et al., 2012; Giraffa, 2012; Martinovic
et al., 2016; Oh et al., 2016). Kefir is another milk-fermented
product that has health promoting bacteria (Prado et al., 2015).
Other non-fermented dairy foods such as low-fat ice cream,
chocolate mousse, coconut flan, or infant milk formula have also
been supplemented with probiotic strains (Davidson et al., 2000;
Aragon-Alegro et al., 2007; Correa et al., 2008; Baglatzi et al.,
2016).
Probiotic microorganisms are generally LAB belonging to
the species Lactobacillus acidophilus, L. gasseri, L. helveticus, L.
johnsonii, L. (para)casei, L. reuteri, L. plantarum, L. rhamnosus,
and L. fermentum, while members of the genus Bifidobacterium
are also used, e.g., Bifidobacterium bifidum, B. longum, B.
animalis, and B. breve (Tamime et al., 2005; Castro et al.,
2015; Linares et al., 2016b). On the basis of the currently
available literature, probiotics can balance intestinal microbiota,
and thereby regulate proper intestinal function and be effective in
the prevention or treatment of several gastrointestinal disorders
such as infectious diarrhea, antibiotic-related diarrhea, irritable
bowel syndrome or Crohn’s disease (Vanderhoof and Young,
1998) Other examples of health benefits promoted by probiotics
supplied via dairy products are inmmunomodulatory effects
(L. casei CRL431), reduction of serum cholesterol level (L. reuteri
NCIMB 30242) and antihypertensive effects (L. plantarum
TENSIATM) (EFSA, 2011; Jones et al., 2012; Aragon et al., 2014).
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Probiotics are defined as ‘live micro-organisms, which when
consumed in adequate amounts confer a health benefit on
the host’ (FAO/WHO, 2001). However, regarding probiotic
foods, some considerations are of paramount importance. Firstly,
effective levels of the live probiotic in the corresponding food
matrix at the time of ingestion are required. In this regard, the
minimum effective dose which affects the intestinal environment
and provides beneficial effects on human health is considered to
be 106–109 live microbial cells per day, although this depends on
the particular strain and foodstuff (Williams, 2010; Karimi et al.,
2012; Watson and Preedy, 2015). Since probiotics show beneficial
health effects on the host once consumed, another precondition
for a bacterial strain to be called probiotic is the ability to
survive and colonize (at least transiently) the gastrointestinal
tract (GIT), which is in part helped by the buffering capacity
of the food matrix. In some particular cases, bacterial viability
may not be strictly required. As an example, inactivated and
dead L. rhamnosus GG cells can maintain immunological and
health-promoting effects (Ghadimi et al., 2008; Lopez et al.,
2008).
Bioactive Compounds Derived from
Microbes
Microorganisms involved in dairy fermentations can produce
biologically active molecules and enzymes, giving the final food
product an additional health value. Unlike the probiotic concept
(the bacteria must be ingested alive and produce the beneficial
metabolite in the body), the biofunctional concept is generally
used when the healthy metabolite emerge in the food product
itself during the fermentation process as a consequence of the
bacterial metabolic activity. Consequently, the bacteria can act
as a microbial factory to enrich foodstuff, for which bacterial
viability through the GIT or during the product storage is
not absolutely required (Farnworth and Champagne, 2015).
The main bioactive compounds produced by LAB during dairy
fermentation are vitamins, gamma-aminobutyric acid, bioactive
peptides, bacteriocins, enzymes, conjugated linoleic acid, and
exopolysaccharides (Table 1).
Vitamins
There are 13 vitamins that must be obtained exogenously due
to the inability of humans to synthesize them; thereby they are
essential nutrients in the human diet, and although in small
amounts, a daily requirement is necessary to prevent deficiencies.
Although most vitamins are present in a variety of foods, human
vitamin deficiencies still occur in many countries, mainly because
of malnutrition, not only as a result of insufficient food intake but
also because of unbalanced diets (LeBlanc et al., 2011).
Although milk contains many vitamins fermentation by LAB
and bifidobacteria constitute an effective way to increase vitamin
levels in milk (Laiño et al., 2013). Some bacterial strains included
in the genera Lactobacillus and Bifidobacterium can provide an
additional source of B vitamins (thiamine, riboflavin, cobalamin,
folate, and biotin) during dairy fermentation. Deficiencies in
riboflavin (vitamin B2) or thiamine (vitamin B1) can lead
to both liver and skin disorders and alterations in brain
glucose metabolism, respectively (Russo et al., 2014). In this
regard, L. casei KNE-1 has been shown to produce thiamine
and riboflavin in fermented milk drinks (Drywien et al.,
2015). B. infantis CCRC14633 and B. longum B6 strains have
been reported to produce riboflavin and thiamine during
soymilk fermentation (Tamime, 2006). It was recently indicated
that soymilk fermented by the riboflavin-producing strain
L. plantarum CRL2130 was able to prevent ariboflavinosis and
experimental colitis in a murine model (Juarez del Valle et al.,
2016; Levit et al., 2016). Some propionibacteria can produce
cobalamin, folic acid, and biotin (Hugenholtz et al., 2002).
Folate (vitamin B9) is involved in several vital processes and
its deficiency is generally linked to neural tube defects, certain
forms of cancer, poor cognitive performance and coronary heart
diseases. Even though vitamins are widely present in foods, the
prevalence of folate deficiency -especially among women of child
bearing age- is a growing concern and thereby folate fortification
programs have been implemented in various countries (Divya
and Nampoothiri, 2015). Rather than incorporating synthetic
folate, foods can be naturally fortified with folate synthesized
by LAB and bifidobacteria during manufacture of fermented
foods (Lin and Young, 2000; Saubade et al., 2016). The strains
Streptococcus thermophilus CRL803/CRL415 and L. bulgaricus
CRL871 were reported to be suitable for the elaboration of
yogurt naturally bio-enriched in this vitamin (Laiño et al., 2013).
High folate concentration (up to 150 µg/l) can be reached in
yogurt as a result of the ability of S. thermophilus to produce
this vitamin (Hugenholtz et al., 2002). Among bifidobacteria,
B. catenulatum ATCC 27539 was shown to produce high levels
of folate in vitro (D’Aimmo et al., 2012), and B. lactis CSCC5127,
B. infantis CSCC5187, and B. breve CSCC5181 strains increased
folate concentration during fermentation of reconstituted skim
milk (Crittenden et al., 2003). Similarly, L. amylovorus CRL887
can be used for natural folate bio-enrichment of fermented milk
(Laiño et al., 2014).
The deficiency of cobalamin (vitamin B12) can be common,
particularly in vegetarians who avoid ingestion of animal protein
and use soymilk as an alternative to dairy milk (Gu et al.,
2015). Animals, plants and fungi are incapable of producing this
vitamin, and hence, it is exclusively produced by microorganisms
(LeBlanc et al., 2011). It has been demonstrated that cobalamin
can be synthesized by some bacteria such as L. reuteri ZJ03,
Propionibacterium freudenreichii, B. animalis Bb12 in soy-yogurt,
kefir and fermented milk, respectively (Van Wyk et al., 2011; Patel
et al., 2013, Gu et al., 2015; Moslemi et al., 2016). Microorganisms
can biosynthesize two different isoforms, the vitamin and the
pseudovitamin. For example, in a recent work, the production
of vitamin and pseudovitamin B12 by P. freudenreichii was
quantified specifically and shows that at the initial phase of the
fermentation both isoforms are biosynthesized at similar levels;
however, by the end of the fermentation the pseudovitamin is not
detected, most likely because it is converted to the vitamin form
(Deptula et al., 2017). It seems crucial to differentiate between
the two isoforms of this vitamin, as the transporter protein in the
human GIT has very low affinity for the pseudovitamin, making
it un-available to humans (Varmanen et al., 2016).
Biotin (vitamin B7) deficiency can be caused by inadequate
dietary intake or some inborn genetic disorders that affect its
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TABLE 1 | Some strains of lactic acid bacteria, bifidobacteria and propionibacteria with potential to biosynthesize health-promoting compounds in
fermented dairy products.
Bioactive Producer strain Food Product Health effect Reference
Thiamine (B1)/Riboflavin (B2) Lactobacillus casei KNE-1 Fermented milk Vitamin enrichment Drywien et al., 2015
Bifidobacterium infantis CCRC14633 Fermented soymilk Vitamin enrichment Tamime, 2006
Bifidobacterium longum B6 Fermented soymilk Vitamin enrichment Tamime, 2006
Lactobacillus plantarum CRL 2130 Fermented soymilk Vitamin enrichment Levit et al., 2016
Biotin (Vitamin B7) Lactobacillus helveticus MTCC5463 Fermented milk Vitamin enrichment Patel et al., 2013
Cobalamin (Vitamin B12) Propionibacterium freudenreichii Kefir Vitamin enrichment Van Wyk et al., 2011
Bifidobacterium animalis Bb12 Fermented milk Vitamin enrichment Patel et al., 2013
Lactobacillus reuteri ZJ03 Soy-yogurt Vitamin enrichment Gu et al., 2015
Folic acid (Vitamin B9) Streptococcus thermophilus
CRL803/CRL415
Yogurt Vitamin enrichment Laiño et al., 2013
Lactobacillus bulgaricus CRL871 Yogurt Vitamin enrichment Laiño et al., 2013
Bifidobacterium lactis CSCC5127 Fermented milk Vitamin enrichment Crittenden et al., 2003
Bifidobacterium infantis CSCC5187 Fermented milk Vitamin enrichment Crittenden et al., 2003
Bifidobacterium breve CSCC5181 Fermented milk Vitamin enrichment Crittenden et al., 2003
Lactobacillus amylovorus CRL887 Fermented milk Vitamin enrichment Laiño et al., 2014
GABA Lactobacillus casei Shirota Fermented milk Antidiabetic, blood
pressure
Inoue et al., 2003
Streptococcus salivarius fmb5 Fermented milk Antidiabetic, blood
pressure
Chen et al., 2016
Lactobacillus plantarum NDC75017 Fermented milk Antidiabetic, blood
pressure
Shan et al., 2015
Lactobacillus brevis OPY-1 Fermented soya milk Antidiabetic, blood
pressure
Park and Oh, 2007
Streptococcus thermophilus APC151 Yogurt Antidiabetic, blood
pressure
Linares et al., 2016a
Bioactive peptides Lactobacillus helveticus Evolus R© Fermented milk Anti-hypertensive EFSA, 2008
Lactobacillus helveticus/S. cerevisiae
(CalpisTM)
Fermented milk Anti-hypertensive Dziuba and Dziuba,
2014
Lactobacillus bulgaricus LB340 Fermented milk/yogurt Anti-hypertensive,
Immunomodulatory
Qian et al., 2011
Bacteriocins Lactococcus lactis CNRZ150/TAB50 Camembert/Semihard cheese Pathogen inhibition Arques et al., 2015
Lactococcus lactis DPC3147 Cheddar cheese Pathogen inhibition Ross et al., 1999
Lactobacillus acidophilus CH5 Yogurt Pathogen inhibition Ahmed et al., 2010
Pediococcus acidilactici CHOOZITTM Cheddar/Semihard cheese Pathogen inhibition Arques et al., 2015
Lactobacillus plantarum WHE92 Munster cheese Pathogen inhibition Arques et al., 2015
Conjugated linoleic acid Lactococcus lactis CI4b Cheddar cheese Cholesterol lowering Mohan et al., 2013
Lactobacillus rhamnosus C14,
Lactobacillus casei CRL431,
Streptococcus thermophilus CRL728,
Bifidobacterium bifidum CRL1399
Buffalo cheese Cholesterol lowering Van Nieuwenhove
et al., 2007a
Lactococcus lactis LMG, Lactobacillus
acidophilus Lac1, Lactobacillus plantarum
-2, Bifidobacterium animalis Bb12
Fermented buffalo milk Cholesterol lowering Van Nieuwenhove
et al., 2007b
Lactobacillus bulgaricus
LB430/Streptococcus thermophilus TA040
Yogurt Cholesterol lowering Sosa-Castañeda et al.,
2015
Exopolysaccharides Lactobacillus bulgaricus OLL1073R-1 Yogurt Immunostimulatory Makino et al., 2016
Lactobacillus mucosae DPC 6426 Yogurt/Cheddar cheese Hypocholesterolemic Ryan et al., 2015
Propionibacterium freudenreichii
KG15/KG6
Turkish cheese Microbiota modulation Darilmaz and
Gumustekin, 2012
Lactococcus lactis SMQ-461 Cheddar cheese Microbiota modulation Dabour et al., 2005
Lactobacillus plantarum YW11 Kefir Microbiota modulation Wang et al., 2015
Bifidobacterium longum CCUG52486 Yogurt Immune modulation Prasannaa et al., 2013
Streptococcus thermophilus zlwTM11 Yogurt Microbiota modulation Han et al., 2016,
Streptococcus thermophilus
FD-DVSST-BODY3
Fermented ice-cream Microbiota modulation Dertli et al., 2016
Frontiers in Microbiology | www.frontiersin.org 4 May 2017 | Volume 8 | Article 846
fmicb-08-00846 May 16, 2017 Time: 17:40 # 5
Linares et al. LAB for Biofunctional Dairy Foods
metabolism. Subclinical deficiency can cause mild symptoms,
such as hair thinning or skin rash typically on the face. Biotin can
be synthesized by some LAB in dairy products, e.g., L. helveticus
MTCC 5463 increased biotin content in fermented milks (Patel
et al., 2013). Some propionibacteria can also produce biotin
(Hugenholtz et al., 2002).
Vitamin K is an important promoter of bone and
cardiovascular health. It has been associated with the inhibition
of arterial calcification and stiffening, and the reduction of
vascular risk. This vitamin is nearly non-existent in junk food,
with little being consumed even in a healthy Western diet
(Maresz, 2015). Its deficiency has been implicated in several
clinical ailments such as intracranial hemorrhage in newborn
infants and possible bone fracture resulting from osteoporosis
(LeBlanc et al., 2011). Vitamin K occurs in two forms: firstly,
phylloquinone (vitamin K1), which is present in green plants,
and secondly, menaquinone (vitamin K2), which is produced
by some intestinal bacteria (LeBlanc et al., 2011). Menaquinone
can be biosynthesized by some LAB species (mainly Lactococcus
lactis) commonly used in industrial fermentation of cheese,
buttermilk, sour cream, cottage cheese, and kefir (Walther
et al., 2013). Other LAB have been screened for the ability to
produce menaquinone; these included strains from the genera
Lactococcus, Bifidobacterium, Leuconostoc, and Streptococcus
(Morishita et al., 1999). Although the MK forms are ubiquitous
in bacteria, it should be noted that some genera such as
Lactobacillus have lost the functional ability to produce them
(Lechardeur et al., 2011; Walther et al., 2013).
Gamma-Aminobutyric Acid
Gamma-aminobutyric acid (GABA) is the main inhibitory
neurotransmitter of the central nervous system (CNS).
Several important physiological functions of GABA have
been characterized, such as neurotransmission, induction
of hypotension, diuretic effects, antidiabetic, relaxing and
tranquilizer effects (Inoue et al., 2003; Marques et al., 2016). In
fact, some GABAA-receptor agonist drugs (e.g., benzodiazepines)
are important pharmacological agents used for clinical treatment
of anxiety (Foster and Kemp, 2006).
Gamma-aminobutyric acid is biosynthesized through
α-decarboxylation of glutamate, an enzymatic conversion
which is catalyzed by glutamate decarboxylase (GAD) (Tajabadi
et al., 2015). Several food-grade LAB have been reported to
exhibit GABA-producing ability. Among them, most of the
GABA-producing strains are lactobacilli (L. brevis, L. paracasei,
L. delbrueckii, L. buchneri, L. plantarum, L. helveticus),
Streptococcus thermophilus, and Lactococcus lactis (Li and
Cao, 2010; Dhakal et al., 2012). Some, Bifidobacterium spp. were
also reported to produce GABA, although with lower capacity
than LAB (Park et al., 2005; Barrett et al., 2012).
Some fermented dairy products enriched in GABA using
GABA-producing LAB as starters have been developed. The
strains L. casei Shirota, S. salivarius fmb5 and L. plantarum
NDC75017 were utilized to ferment and enrich milk in GABA
(Inoue et al., 2003; Shan et al., 2015; Chen et al., 2016). More
recently, yogurt enriched with 2 mg GABA/ml was produced
using the strain S. thermophilus APC151 (Linares et al., 2016a,
2017). Also, fermented soya milk (using L. brevis OPY-1 as
source of GABA) (Park and Oh, 2007), or cheese (Lactococcus
lactis as source of GABA) (Nomura et al., 1998; Pouliot-Mathieu
et al., 2013) have been produced. Thus, GABA has potential as
a health-promoting bioactive component in foods (Li and Cao,
2010).
Bioactive Peptides
During milk fermentation, LAB, making use of their proteolytic
system can transform milk proteins into biologically active
peptides. These peptides can exert a wide range of effects,
such as antimicrobial, antihypertensive, antithrombotic,
immunomodulatory, and antioxidative (LeBlanc et al., 2002;
Nongonierma and FitzGerald, 2015). The most studied
mechanism of bioactive peptides is the antihypertensive action
displayed by the inhibition of the angiotensin-I-converting
enzyme (ACE; peptidyldipeptide hydrolase, EC 3.4.15.1) which
regulates blood pressure (Fernandez et al., 2015). ACE inhibitory
peptides have been isolated from a variety of fermented
dairy products including cheese, fermented milks and yogurt
(Fitzgerald and Murray, 2006; Pritchard et al., 2010). The best
known ACE-inhibitory biopeptides, Val-Pro-Pro (VPP) and
Ile-Pro-Pro (IPP), have been identified in milk fermented by
L. helveticus (Slattery et al., 2010). In addition, other dairy starter
cultures industrially used in the manufacture of fermented dairy
products (e.g., L. helveticus, L. delbrueckii ssp. bulgaricus, L.
plantarum, L. rhamnosus, L. acidophilus, Lactococcus Lactis, or
S. thermophilus) can generate bioactive peptides (Hajirostamloo,
2010; Hafeez et al., 2014). Other ACE-inhibitory peptides such
as β-casein f(72-81), Ser-Lys-Val-Tyr-Pro-Phe-Pro-Gly-Pro-Ile
(SLVYPFPGPI) have been produced by L. delbrueckii ssp.
bulgaricus LB340 in fermented milk (Qian et al., 2011).
On an industrial scale, two fermented milk products with
antihypertensive claims, CalpisTM and Evolus R©, have been tested
extensively in rats and in clinical trials, and are commercialized as
functional foods (Dziuba and Dziuba, 2014). Evolus R© is available
in the market as a L. helveticus fermented milk -produced
in Finland- proven to decrease the systolic blood pressure in
hypertensive subjects due to the actions of L. helveticus bioactive
peptides (EFSA, 2008). CalpisTM is defined as a milk product
marketed in Japan (Calpis Co. Ltd.) with antihypertensive
properties. It is prepared by fermenting skimmed milk with
L. helveticus and Saccharomyces cerevisiae, which produce VPP
and IPP peptides from β-casein and κ-casein (Dziuba and
Dziuba, 2014).
Bacteriocins
Bacteriocins are ribosomally synthesized antimicrobial peptides
produced by a particular bacterium that are active against
other competitor bacteria; thereby they constitute an important
part of the microbial defense system (Nes et al., 2007).
Such bacteriocin-producing strains may offer potential as an
alternative to antibiotics, and may be useful as a means of
controlling pathogen carriage, therefore being highly suitable
as microbial food additives (Cotter et al., 2013) (Table 2).
Bacteriocins from LAB have attracted much interest because
they are frequently produced by commercially useful strains that
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TABLE 2 | Characteristic aspects of bacteriocins compared to
conventional antibiotics (Adapted from Cleveland et al., 2001).
Bacteriocins Antibiotics
Application Foods Clinical
Bioactivity spectra Mostly narrow Mostly broad
Bioactivity intensity nM – µM µM – mM
Biosynthesis Ribosomal Secondary metabolite
Proteolytic degradability High None
Thermostability High Low
Activity pH range Wide Narrow
Target cell resistance
development
Adaptation through
changes in cell
membrane composition
Genetically transferable
determinant that
inactivates the active
compound
Mode of action Generally, pore
formation.
Cell membrane or
intercellular targets,
inhibition of cell wall
biosynthesis
Toxicity in eukaryotic
cells
None known Present
are generally regarded as safe (GRAS) for human consumption
(Nes et al., 2007). These antimicrobial molecules are among
the beneficial peptides intrinsically synthesized by some LAB
during milk fermentation and they have been traditionally used
as naturally produced food biopreservatives. In addition, they
may function in the GIT as potential natural biotherapeutic
agents facilitating the competition of probiotic strains and/or
inhibition of pathogens; thereby they are potential contributors
to the microbiota balance and human health (Dobson et al.,
2012).
Nisin is the most well-known bacteriocin used as food
preservative due to its antibacterial effect against Listeria,
clostridia spores and LAB associated to spoilage. Nisin has
been approved as a food additive (E234) in the European
Union according to Directive 95/2/EC (EC, 1995) in the
following products: semolina and tapioca puddings (3 mg/kg);
ripened and processed cheese (12.5 mg/kg), clotted cream
(10 mg/kg), and Mascarpone cheese (10 mg/kg). It is also
permitted in over 40 countries world-wide including USA,
Australia, South Africa, Russia, and India for use as an
antimicrobial agent in a variety of food products (EFSA,
2006). Nisin-containing Camembert and semihard cheeses with
prolonged shelf-life were made using Lactococcus lactis (strains
CNRZ150 or TAB50, respectively) as nisin producers (Arques
et al., 2015). Apart from nisin, plantaricins are very well-
known bacteriocins. For example, plantaricin C is a broad
spectrum bacteriocin produced by L. plantarum, isolated from
ripening cheese (Gonzalez et al., 1994). Plantaricins have
been reported to produce an immunomodulatory effect on
dendritic cells (Meijerink et al., 2010). However, bacteriocins
other than nisin have so far only few and limited authorized
uses in foods (Yang et al., 2015). Consequently, the use of
bacteriocin-producing bacteria as starter culture for in situ
biosynthesis during milk fermentation becomes an effective
alternative strategy to incorporate bacteriocins in dairy foods.
Similarly, the lacticin 3147-producing strain Lactococcus lactis
DPC3147 used as a protective culture in Cheddar cheese reduced
numbers of Listeria monocytogenes to <10 cfu/g within 5 days
at 4◦C (Ross et al., 1999; Chen and Hoover, 2006). Other
bacterial species such as L. acidophilus can be added as an
adjunct in many food fermentation processes to contribute to
bacteriocin production and food preservation (Anjum et al.,
2014). Other LAB strains such as L. plantarum WHE92 used
as adjunct to the starter culture reduced Listeria monocytogenes,
Listeria innocua, and Escherichia coli O157:H7 counts in cheese
as a consequence of the production of plantaricin (Arques
et al., 2015). Using a similar concept, Danisco developed
a freeze-dried culture of Pediococcus acidilactici (marketed
as CHOOZIT Flav 43) for use as a bacteriocin-producer
adjunct in Cheddar and semihard cheeses (Mills et al.,
2011).
Studies of the direct impact of dairy foods containing
bacteriocins on human health and microbiome are
still limited. In vivo antimicrobial activity of nisin and
lacticin 3147 has been recently demonstrated in a murine
infection model. A nisin-producing Lactococcus lactis
CHCC5826 modified the microbiota composition of human
microbiota-associated rats increasing bifidobacteria levels and
decreasing Enterococcus/Streptococcus populations. Lacticin
3147 has the potential to be employed in the treatment of
Clostridium difficile diarrhea and to eliminate the pathogen
when added to an anaerobic fecal fermentation (Arques et al.,
2015).
Enzymes
Lactic acid bacteria associated to dairy fermentations possess
enzymes which can be produced in situ during fermentation
of dairy foods and have bioactive potential on the consumer.
Examples are hydrolytic enzymes that may exert potential
synergistic effects on digestion and alleviate symptoms of
intestinal malabsorption (Patel et al., 2013). A well-known
example is the β-galactosidase activity, which can achieve
lactose degradation and thereby improve health and reduce
symptoms of lactose intolerant consumers. Yogurt and other
conventional starter cultures and probiotic bacteria in fermented
and unfermented milk products improve lactose digestion and
alleviate symptoms of intolerance in lactose malabsorbers. These
beneficial effects are due to microbial β-galactosidase (de Vrese
et al., 2001).
Conjugated Linoleic Acid
Conjugated linoleic acid (CLA) is a polyunsaturated fatty acid
(PUFA) that can be biosynthesized by LAB and bifidobacteria
through bioconversion of linoleic acid (LA; cis-9,cis-12 C18:2).
The two isomers that have been shown to have bioactive potential
are cis-9,trans-11 (c9,t11) and trans-10,cis-12 (t10,c12). The
health-promoting properties of CLA include anticarcinogenic,
antiatherogenic, anti-inflammatory, and antidiabetic activity, as
well as the ability to reduce body fat (Sosa-Castañeda et al., 2015).
Although it is a native component of milk, the amount consumed
in foods is far from that required in order to obtain desired
beneficial effects. Thus, increasing the CLA content in dairy foods
Frontiers in Microbiology | www.frontiersin.org 6 May 2017 | Volume 8 | Article 846
fmicb-08-00846 May 16, 2017 Time: 17:40 # 7
Linares et al. LAB for Biofunctional Dairy Foods
through milk fermentation with specific LAB offers a promising
alternative. An effective way to increase CLA uptake in humans
is to increase CLA levels in dairy products by using strains
with high production potential (Lee et al., 2007). A number of
food-grade LAB and bifidobacteria were reported to produce
CLA in milk products (Sosa-Castañeda et al., 2015; Yang et al.,
2015), as is the case of Lactococcus lactis LMG, L. rhamnosus
C14, L. casei CRL431, L. acidophilus Lac1, L. plantarum-2,
B. bifidum CRL1399 and B. animalis Bb12 (Van Nieuwenhove
et al., 2007a; Florence et al., 2009). Some of these strains
were also used as adjunct cultures for the manufacture of high
CLA-content buffalo cheese (Van Nieuwenhove et al., 2007b).
The CLA-producing starter culture of Lactococcus lactis CI4b
enhanced levels of total CLA in Cheddar cheese (Mohan et al.,
2013). Similarly, L. bulgaricus LB430 and S. thermophilus TA040
are suitable for production of CLA-enriched yogurt (Florence
et al., 2009).
In addition, it has been shown that specific microorganisms
such as L. plantarum PL60 or B. breve NCIMB702258, are
able to produce CLA following dietary administration in
animal models (Wall et al., 2009, 2012) and following
the administration as a freeze-dried product in humans
(Lee and Lee, 2009). Thus, intestinal CLA production
by bacteria may contribute to enhance CLA supply in
addition to the CLA provided by the producing strain
in fermented milks during the manufacture (Teran et al.,
2015).
Exopolysaccharides
Exopolysaccharides (EPS) are complex extracellular
carbohydrate polymers that can be produced by some LAB
in situ during dairy fermentations. Some of them promote
selective growth of bifidobacteria, thus playing a role on the host
microbiota and immune system (Fernandez et al., 2015; Salazar
et al., 2016). In this regard, EPS derived from yogurt fermented
with L. delbrueckii ssp. bulgaricus OLL1073R-1 exerted immune-
stimulatory effects in mice (Makino et al., 2016). Yogurt,
Swiss-type, and Cheddar cheeses represent suitable food matrices
for the delivery of the hypocholesterolemic EPS-producer strain
L. mucosae DPC 6426 (Ryan et al., 2015). Other microorganisms
with potential to produce EPS in cheese are P. freudenreichii
KG15/KG6, Lactococcus lactis SMQ-461 or S. thermophilus
MR-1C (Dabour et al., 2005; Darilmaz and Gumustekin, 2012).
Significant levels of EPS can also be produced in kefir by
L. plantarum YW11 (Wang et al., 2015). Recently, EPS produced
by bifidobacteria have attracted the attention due to their
immune modulation capability (Hidalgo-Cantabrana et al.,
2012).
Exopolysaccharides can also improve the quality, sensory
and rheological properties of the final food product, which in
many cases results in a reduction of the amount of chemical
stabilizers required, thus favoring a more natural product. For
example, strains of B. longum subsp. infantis CCUG 52486
and S. thermophilus were suitable to produce yogurt and
fermented ice-cream with improved viscosity and texture and
reduced syneresis as a consequence of their high EPS production
(Prasannaa et al., 2013; Han et al., 2016; Dertli et al., 2016).
REGULATORY ASPECTS
At present, the status of probiotic-based products is full of
ambiguities because various regulatory agencies in different
countries are defining and categorizing probiotics differently.
Despite the emerging interest of consumers toward probiotics
and functional foods, in Europe the regulatory framework is still
not harmonized and no health claim for probiotics alone (except
yogurt starters) has been approved. Paradoxically, probiotics or
bioactive bacteria have been introduced into the market as dietary
supplements or natural health products (capsules, tablets, and
powders) (Arora and Baldi, 2015). Japan was the very first global
jurisdiction for implementing a regulatory system for functional
foods and nutraceuticals in 1991, and is currently acting as global
market leader where probiotics are available as both foods and
drugs. The government has designated Foods for Specific Health
Uses (FOSHU), which classifies health claims into different
subcategories (gastrointestinal health, cholesterol moderation,
hypertension moderation, lipid metabolism moderation, sugar
absorption moderation, mineral absorption, and bone and tooth
health). In China, State Food and Drug Administration (SFDA)
has regulated all health foods including functional foods and
nutraceuticals, and a well-developed market for functional
foods is established (Arora and Baldi, 2015). Currently USA
is regulating probiotics as a variety of products as per their
intended usage and regulatory bodies are Dietary Supplement
Health and Education Act (DSHEA) and Food and Drug
administration (FDA). Dietary supplements are considered as
‘foods’ and are regulated by DSHEA and do not need FDA
approval before being marketed. However, probiotics and dietary
supplements containing a new dietary ingredient without a
marketing history are regulated by FDA. In conclusion, a
harmonized categorization of probiotics and functional foods
may help to regulate these products whenever solid clinical
documentation is available to support any health effects and
health messages in human subjects. The appropriate level of
evidence for determining a health benefit for probiotics should
always be put ahead of commercial and labeling industrial
interests.
CHALLENGES IN INDUSTRY AND
CONCLUDING REMARKS
A goal of the dairy industry is to develop novel dairy products
with increased nutritional and/or health promoting properties.
Food-grade bacteria have the potential to fortify fermented
dairy food products with bioactive metabolites by a natural
process, thereby reducing the need for fortification with costly
chemically synthesized supplements. Nowadays, a number of
commercial sources have available synthetic formulations of
bioactive substances for their use as a dietary supplement. The use
of health-supporting bacteria for naturally enriching dairy foods
with bioactives could be a suitable alternative to food fortification
with chemical formulations.
The starter cultures must be carefully selected, since the
ability of microbial cultures to produce bioactive metabolites is
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generally a strain-dependent trait and varies considerably among
strains within the same species. The yield of bioactive synthesis
and the concentration of such compound in dairy products
is another critical strain-dependent factor. In this regard, the
dose of bioactives ingested with the corresponding food product
should remain over the minimum required to meet the human
requirements and/or have the claimed therapeutic level on the
consumer, according to existing clinical recommendations and
studies. An open question when using co-cultures or strain
combinations is their interaction in terms of nutrient availability,
bacterial growth, as well as the bioactive production yield. In
some cases, metabolites (i.e., vitamins etc.) produced by one
of the strains could be consumed by the other strains, thus
decreasing the final content in food.
Generally, the biosynthetic pathways are genetically encoded.
In this regard, the increasing availability of bacterial genome
sequences over the last decade has provided a major contribution
to the knowledge about microbial production of bioactive
molecules. However, the presence of the genes required
for the biosynthesis of a particular biomolecule should not
be assumed as synonym of metabolite production. Typical
exceptions to the correlation genotype-phenotype occur
when the genes are not active or when the metabolite
is intracellularly biosynthesized and a release system is
lacking. This is indeed one of the major bottlenecks during
biosynthesis of some vitamins that needs to be overcome
through the use of alternative strategies such as autolytic
mutants and metabolic engineering (Basavanna and Prapulla,
2013).
Consideration should also be given by manufacturers to the
optimum conditions for bioactive compound biosynthesis by
LAB during technological processes. The content and activity
of a bioactive compound in the dairy fermented foodstuffs is
the result of the type of food matrix, the individual bacterial
strain properties as well as the processing conditions and storage
time. In this regard, it should be noted that the high bioactive
biosynthetic rates observed in culture media might not always be
extrapolated to dairy products. Therefore, factors such as optimal
temperature for microbial growth and viability, food composition
or bioactive stability and shelf-life in the final foodstuff are of
paramount importance to reach the maximum concentration and
activity in the final product.
Overall, the current review updates knowledge about LAB,
bifidobacteria and propionibacteria with potential to enrich dairy
food products with health-promoting bio-metabolites. Promising
applications at commercial level emerge; however, adequate
selection of strains is vital to increase the concentration and
bioavailability of such biomolecules in fermented foods. The
use of LAB and bifidobacteria able to synthesize bioactive
components in fermented foods could help to provide these
compounds in foods, this being in compliance with current
regulatory rules.
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